Breyanzi car t therapy for tvhs transplant center
Ended Awarded
- Contract number
- 36C24926N0232
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 9
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $335,043
Award facts
- Contract value 100% obligated
- $335,042.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lawrenceville, Lawrence Township, NJ 08648, USA
Award details come from SAM.gov/FPDS.
About this award
Bristol-Myers Squibb Company has been awarded a delivery order valued at $335,042.65 by Veterans Integrated Service Network 9 for the supply of BREYANZI CAR T therapy to support the transplant center operations. This firm fixed-price delivery order, awarded on October 27, 2025, with an ultimate completion date of February 6, 2026, will be performed in Lawrenceville, New Jersey. The award carries no set-aside designation, reflecting Bristol-Myers Squibb's status as a large biopharmaceutical manufacturer. BREYANZI is an advanced chimeric antigen receptor T cell therapy used to treat hematologic malignancies, and this delivery order enables the VA to provide this specialized oncology treatment to eligible veterans through the transplant center.
This delivery order is issued under Bristol-Myers Squibb's Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), a multiple-award indefinite delivery/indefinite quantity contract with the Department of Veterans Affairs that carries a substantial ceiling value of $12.3 billion through April 30, 2029. The VA utilizes this master schedule to efficiently procure a comprehensive range of pharmaceutical products with particular emphasis on innovative cancer treatments and specialized cell therapies. As a prime contractor with extensive experience delivering advanced immunotherapy treatments across multiple Veterans Integrated Service Networks, Bristol-Myers Squibb plays a critical role in supporting the VA's mission to deliver state-of-the-art medical care to the veteran population.
Quick answers
Who was awarded contract 36C24926N0232?
36C24926N0232 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 9 (Veterans Health Administration) on October 27, 2025.
How much is contract 36C24926N0232 worth?
The government has obligated $335,043 on 36C24926N0232.
Is contract 36C24926N0232 an order under another contract?
Yes. 36C24926N0232 is a delivery order under 36F79724D0101, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24926N0232 competed?
The extent of competition for 36C24926N0232 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award